Open Access Open Access  Restricted Access Subscription or Fee Access

Drug-likeness and 3D-QSAR Analysis of 1,2,3-triazoles as Novel Potent HIV-1 Vif Inhibitors: An approach in the development of Leads in the Treatment of HIV Infection

Olalekan Ayodele Agede, Louis Okeibunor Odeigah, Maryam Abimbola Jimoh, George Oche Ambrose, Olufunke Esan Olorundare

Abstract


Abstract

The human immunodeficiency virus type 1 (HIV-1) Vif protein is one of various primate lentiviral accessory proteins that act as a virulence factor to advance viral duplication and persistence. 3D quantitative structure-activity relationship (QSAR) modeling of thirty-six (36) newly discovered 1,2,3-triazole analogs as potent novel inhibitors of HIV-1 Vif to predict their biological activity (pIC50), to try to improve/optimize it using some numerical data of HIV-1 Vif inhibitors based on their physical and chemical properties (descriptors). Calculations of various 3D physicochemical properties or descriptors from structures were developed using ChemoPy descriptor software. Furthermore, according to the Kennard-Stone algorithm the dataset is divided into training set and test set. Model acceptance criteria are met due to robust internal and external validation metrics (R2train = 0.92014, adjusted R2 = 0.86309, PRESS = 0.84768, mean R2m(LOO-train) = 0.72925, Q2cv = 0.79701, R2pred = 0.67081, R2test = 0.79701). Most 1,2,3-triazole analogs exhibit good Lipinski parameter properties, with TPSA <40 indicating good permeability in biofilms and gastrointestinal absorption. The proposed model has fine robustness and predictive ability when validated by both internal and external validation. To enhance the biological activity of HIV drugs based on 1,2,3-triazole scaffolds, this model can be applied to rational drug design.

Keywords: QSAR, 1,2,3-triazoles, descriptors, bioactivities, HIV, drug-likeness

Citation: Olalekan Ayodele Agede, Louis Okeibunor Odeigah, Maryam Abimbola Jimoh, George Oche Ambrose, Olufunke Esan Olorundare. Drug-likeness and 3D-QSAR Analysis of 1,2,3-triazoles as Novel Potent HIV-1 Vif Inhibitors: An Approach in the Development of Leads in the Treatment of HIV Infection. Research & Reviews: A Journal of Drug Design & Discovery. 2022; 9(3): 23–37p.


Full Text:

PDF

References


Mehellou Y, Clercq ED. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem. 2010; 53: 521–538

Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304: 321–333.

Malim, M.H., &Emerman, M. (2008). HIV-1 accessory proteins—ensuring viral survival in a hostile environment. Cell host & microbe, 3 (6), 388-398.

Gramberg, T., Sunseri, N., & Landau, N.R. (2009). Accessories to the crime: recent advances in HIV accessory protein biology. Current HIV/AIDS Reports, 6 (1), 36–42.

Gabuzda, D.H., Lawrence, K., Langhoff, E.E.A., Terwilliger, E., Dorfman, T., Haseltine, W. A., &Sodroski, J. (1992). Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. Journal of virology, 66 (11), 6489–6495.

Sakai, H. I. R. O. Y. U. K. I., Shibata, R. I. R. I., Sakuragi, J. L., Sakuragi, S. A. Y. U. R. I., Kawamura, M. E. I. K. O., & Adachi, A. K. I. O. (1993). Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. Journal of virology, 67 (3), 1663–1666.

von Schwedler, U., Song, J. I. N. P. I. N. G., Aiken, C. H. R. I. S. T. O. P. H. E. R., &Trono, D. I. D. I. E. R. (1993). Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. Journal of virology, 67 (8), 4945–4955.

Sharkey, M., Sharova, N., Mohammed, I., Huff, S. E., Kummetha, I. R., Singh, G., ... & Stevenson, M. (2019). HIV-1 escape from small-molecule antagonism of Vif. Mbio, 10 (1), e00144-19.

Mohammed, I., Kummetha, I. R., Singh, G., Sharova, N., Lichinchi, G., Dang, J., ... & Rana, T. M. (2016). 1, 2, 3-Triazoles as amide bioisosteres: discovery of a new class of potent HIV-1 Vif antagonists. Journal of medicinal chemistry, 59 (16), 7677–7682.

Verma J, Khedkar VM, Coutinho EC. 3d-qsar in drug design-a review. Curr Top Med Chem. 2010; 10 (1): 95–115.

Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep neural nets as a method for quantitative structure–activity relationships. J Chem Inf Model. 2015; 55 (2): 263–74.

Golbraikh A, Wang XS, Zhu H, Tropsha A. Predictive qsar modeling: methods and applications in drug discovery and chemical risk assessment. HandbComput Chem. 2016:1–48

Mohammed, I., Kummetha, I.R., Singh, G., Sharova, N., Lichinchi, G., Dang, J., ... & Rana, T. M. (2016). 1, 2, 3-Triazoles as amide bioisosteres: discovery of a new class of potent HIV-1 Vif antagonists. Journal of medicinal chemistry, 59 (16), 7677-7682.

Gaulton, A., Hersey, A., Nowotka, M., Bento, A.P., Chambers, J., Mendez, D., ... & Leach, A. R. (2017). The ChEMBL database in 2017. Nucleic acids research, 45 (D1), D945–D954.

López-López, E., Naveja, J.J., & Medina-Franco, J.L. (2019). DataWarrior: An evaluation of the open-source drug discovery tool. Expert Opinion on Drug Discovery, 14 (4), 335–341.

Cao, D.S., Xu, Q.S., Hu, Q.N., & Liang, Y.Z. (2013). ChemoPy: freely available python package for computational biology and chemoinformatics. Bioinformatics, 29 (8), 1092–1094.

Mackert, M., Guadagno, M., Mabry, A., &Chilek, L. (2013). DTC drug advertising ethics: Laboratory for medical marketing. International Journal of Pharmaceutical and Healthcare Marketing.

Dharmendra K YadavSurendra Kumar SaloniHarpreet Singh Mi-hyun Kim1 Praveen Sharma SanjeevMisraFeroz Khan. Molecular docking, QSARand ADMET studies of withanolide analogs against breast cancer. Drug Design, Development and Therapy. 2017: Nov. 1859–1870

Tropsha, A. (2010). Best practices for QSAR model development, validation, and exploitation. Mol Inform 29: 476–488.

Yadav DK, Khan F. QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase‐I. Journal of Chemometrics. 2013 Jan; 27 (1-2): 21–33.

K Yadav D, Mudgal V, Agrawal J, K Maurya A, U Bawankule D, S Chanotiya C, Khan F, T Thul S. Molecular docking and ADME studies of natural compounds of Agarwood oil for topical anti-inflammatory activity. Current computer-aided drug design. 2013 Sep 1; 9 (3): 360–70.

Veerasamy, R., Rajak, H., Jain, A., Sivadasan, S., Varghese, C. P., & Agrawal, R.K. (2011). Validation of QSAR models-strategies and importance. Int. J. Drug Des. Discov, 3, 511–519.

Arthur, D. E., Uzairu, A., Mamza, P., Abechi, S. E., &Shallangwa, G. (2020). Activity and toxicity modelling of some NCI selected compounds against leukemia P388ADR cell line using genetic algorithm-multiple linear regressions. Journal of King Saud University-Science, 32 (1), 324–331.

Shinoda, W. (2016). Permeability across lipid membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1858 (10), 2254–2265.

Ambrose GO, Afees OJ, Kalu UJ, Oshireku AW, Todimu AD. QSAR Model Generation of Phthalazinones as Poly (ADP-Ribose) Polymerase Inhibitors by the Genetic Algorithm and Multiple Linear Regression (GA-MLR) Method: A Ligand-Based Approach for Cancer Drug Design. J Proteomics Bioinform. 2018; 11: 183–19

Lipinski, C.A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of pharmacological and toxicological methods, 44 (1), 235–249.

Khan, T.H. (2010). Tareq Hassan Khan M. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches, Curr. Drug Metab, 11, 285–295.

Lipinski, C.A., Lombardo, F., Dominy, B.W., & Feeney, P.J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 23 (1-3), 3–25.

Rudrapal, M., & Sowmya, M.P. (2019). Design, synthesis, drug-likeness studies and bio-evaluation of some new chalconeimines. Pharmaceutical Chemistry Journal, 53 (9), 814–821.

Ibrahim, Z.Y.U., Uzairu, A., Shallangwa, G., &Abechi, S. (2020). Molecular docking studies, drug-likeness and in-silico ADMET prediction of some novel β-Amino alcohol grafted 1, 4, 5-trisubstituted 1, 2, 3-triazoles derivatives as elevators of p53 protein levels. Scientific African, 10, e00570.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: A Journal of Drug Design & Discovery